Patients whose sputum culture yielded organisms other than Streptococcus pneumoniae were categorized as having CAP of non-pneumococcal etiology. Pneumonia severity was assessed using the CURB-65 scoring system. 5 Data analyses were performed using the Epi Info version 3.5.3. Comparisons between cases and controls were carried out using the chi-square or Fisher's exact test for qualitative variables, and Student's t-test or non-parametric equivalents for quantitative variables as appropriate. p-Value <0.05 was considered statistically significant.
The results are shown in Table 1 . HIV-infected patients were significantly younger than the controls (37 vs. 49 years, p = 0.0002), otherwise both groups had similar sociodemographic characteristics and received comparable treatments. While the control group had a higher proportion of patients with sputum production (73 vs. 54%, p = 0.01) and chest pain (28 vs. 14%, p = 0.04); fever (89 vs. 73%, p = 0.02) and breathlessness (75 vs. 58%, p = 0.04) were more frequent in the cases. HIV-infected patients were more likely to have severe pneumonia as assessed by the CURB-65 score (38.7 vs. 6.0%, p < 0.0001), and were also more likely to have anemia (p < 0.0001) and hyperglycemia (p = 0.002). HIV-infected patients had higher in-hospital mortality (54.5 vs. 8.5%, p < 0.0001) and longer LOS among survivors (13 vs.10 days, p = 0.03).
In conclusion, we found that HIV infection negatively impacts on CAP clinical presentation, overall mortality, and LOS among survivors. Corroborating our findings in large prospective cohort studies would have strong implications for the management of CAP in HIV-infected populations especially in sub-Saharan Africa. 
